Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

The study builds on Dr Elias Sayour’s (University of Florida) earlier research and marks a key step toward a universal cancer vaccine that boosts immunotherapy’s effectiveness.

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...

A large-scale MIT screen of tuberculosis proteins revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.

The Packard Center and ALS United will fund a preclinical study investigating how abnormal TDP-43 protein contributes to ALS.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...